tasurgratinib   Click here for help

GtoPdb Ligand ID: 11414

Synonyms: E-7090 | E7090 | Example 22 [WO2014129477A1]
Compound class: Synthetic organic
Comment: The chemical structure for the INN tasurgratinib resolves to E-7090 via PubChem, and is claimed as Example 22 in patent WO2014129477A1 as an inhibitor of FGFR pathway signalling [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 14
Topological polar surface area 127.18
Molecular weight 587.27
XLogP 2.15
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES COCCOc1cc2c(cc1Oc1ccnc(c1)NC(=O)c1ccc(cc1)C1CCN(CC1)CCO)ccn2C(=O)NC
Isomeric SMILES COCCOc1cc2c(cc1Oc1ccnc(c1)NC(=O)c1ccc(cc1)C1CCN(CC1)CCO)ccn2C(=O)NC
InChI InChI=1S/C32H37N5O6/c1-33-32(40)37-14-10-25-19-29(28(21-27(25)37)42-18-17-41-2)43-26-7-11-34-30(20-26)35-31(39)24-5-3-22(4-6-24)23-8-12-36(13-9-23)15-16-38/h3-7,10-11,14,19-21,23,38H,8-9,12-13,15-18H2,1-2H3,(H,33,40)(H,34,35,39)
No information available.
Summary of Clinical Use Click here for help
As of February 2021 the most advanced E-7090 clinical trial was a Phase 2 in subjects with cholangiocarcinoma harbouring FGFR2 fusions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04493255 A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1 Interventional Eisai Inc.
NCT04238715 A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion Phase 2 Interventional Eisai Inc.